Will endothelin receptor antagonists have a role in heart failure?

Med Clin North Am. 2003 Mar;87(2):459-74. doi: 10.1016/s0025-7125(02)00186-4.

Abstract

Mixed ET(A/B) and selective ET(A) receptor antagonists showed promising hemodynamic and symptomatic improvements in patients with heart failure. Randomized, clinical trials to investigate the effects of ET receptor antagonists on survival in patients with heart failure still need to be conducted. Also, the effects of selective ET(A) and mixed ET(A/B) receptor antagonists on the clinical outcome of patients with CHF will have to be assessed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bosentan
  • Cardiovascular Agents / pharmacology*
  • Cardiovascular Agents / therapeutic use*
  • Clinical Trials as Topic
  • Endothelin Receptor Antagonists*
  • Endothelins / metabolism*
  • Heart Failure / drug therapy*
  • Heart Failure / metabolism*
  • Humans
  • Isoxazoles / pharmacology
  • Isoxazoles / therapeutic use
  • Oligopeptides / pharmacology
  • Oligopeptides / therapeutic use
  • Peptides, Cyclic / pharmacology
  • Peptides, Cyclic / therapeutic use
  • Phenylpropionates / pharmacology
  • Phenylpropionates / therapeutic use
  • Piperidines / pharmacology
  • Piperidines / therapeutic use
  • Pyridines / pharmacology
  • Pyridines / therapeutic use
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use
  • Tetrazoles / pharmacology
  • Tetrazoles / therapeutic use
  • Thiophenes / pharmacology
  • Thiophenes / therapeutic use
  • Treatment Outcome

Substances

  • Cardiovascular Agents
  • Endothelin Receptor Antagonists
  • Endothelins
  • Isoxazoles
  • Oligopeptides
  • Peptides, Cyclic
  • Phenylpropionates
  • Piperidines
  • Pyridines
  • Pyrimidines
  • Sulfonamides
  • Tetrazoles
  • Thiophenes
  • darusentan
  • BQ 788
  • tezosentan
  • sitaxsentan
  • Bosentan
  • cyclo(Trp-Asp-Pro-Val-Leu)